TrialBMC cancer2018
Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer.
Marina Pulido et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
20 papers cite it
this papertrialcites it